Gastric cancer diagnostic procedures encompass a wide range of tests and technologies designed to detect and monitor stomach cancer at early stages. These procedures include traditional methods such as endoscopy, biopsy, and imaging tests, as well as advanced approaches like molecular diagnostics, liquid biopsy, and multiplexing assays. The increasing global prevalence of gastric cancer, coupled with growing awareness of early detection, is driving the demand for diagnostic services. Advanced diagnostic technologies enable clinicians to identify biomarkers, including HER2 and PD-L1, which guide personalized treatment strategies and improve patient outcomes.

Market Overview

The gastric cancer diagnostic procedure market is projected to grow from US$ 1.53 billion in 2025 to US$ 2.69 billion by 2034, registering a CAGR of 6.53%. Advancements in non-invasive diagnostics, molecular profiling, and precision medicine are reshaping the market landscape. Hospitals, diagnostic laboratories, oncology specialty clinics, and cancer research institutes are increasingly adopting these advanced procedures to provide accurate diagnosis, staging, and treatment monitoring.

Endoscopic procedures, biopsies, in-vitro diagnostics, imaging tests, and molecular diagnostics constitute the key procedural categories. Endoscopic procedures remain the most widely used due to their ability to visualize tumors and facilitate tissue sampling. Molecular diagnostics and liquid biopsy are rapidly gaining traction, offering less invasive alternatives and enabling personalized therapeutic decisions.

Market Drivers and Opportunities

Several factors are driving the expansion of the gastric cancer diagnostic procedure market:

• Rising global incidence of gastric cancer linked to aging populations, Helicobacter pylori infection, smoking, and dietary factors.
• Increasing adoption of advanced diagnostic technologies, including AI-assisted endoscopy, next-generation sequencing, and liquid biopsy.
• Growing focus on early detection and screening programs in high-incidence regions to improve treatment outcomes.
• Shift toward personalized medicine, allowing tailored treatment plans based on molecular and genetic profiling.
• Development of non-invasive diagnostics that offer patient-friendly, scalable, and cost-effective alternatives.
• Expansion of telemedicine services for follow-up consultations and remote access to diagnostic evaluations.

Key Players

The gastric cancer diagnostic procedure market is highly competitive, with leading companies focusing on innovation, global expansion, and strategic collaborations:

• Atlas-Link Biotech Co Ltd
• Bio-Rad Laboratories Inc
• MiRXES Pte Ltd
• Agilent Technologies Inc
• F. Hoffmann-La Roche Ltd
• bioMerieux SA
• Thermo Fisher Scientific Inc
• Illumina Inc
• Vela Diagnostics Holding Pte Ltd

Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00029842

Future Outlook

The gastric cancer diagnostic procedure market is expected to maintain steady growth through 2034. Increasing awareness of early detection, advancements in molecular diagnostics and liquid biopsy, and the adoption of telemedicine are anticipated to drive market expansion. Emerging markets in Asia-Pacific and Latin America are likely to witness significant growth due to improving healthcare infrastructure, increasing screening programs, and rising incidence of gastric cancer. Companies investing in innovative diagnostic solutions and personalized medicine are well-positioned to capitalize on evolving market opportunities.

Frequently Asked Questions (FAQs)

1. What is a gastric cancer diagnostic procedure?
   A gastric cancer diagnostic procedure is a medical test or technique used to detect, monitor, and assess stomach cancer, including endoscopy, biopsy, imaging, molecular diagnostics, and liquid biopsy.
2. What factors are driving the gastric cancer diagnostic procedure market?
   Market growth is driven by the rising prevalence of gastric cancer, technological advancements in molecular diagnostics and non-invasive tests, early detection initiatives, and the focus on personalized medicine.
3. Which regions are expected to see significant growth in the gastric cancer diagnostic procedure market?
   Asia-Pacific and Latin America are expected to experience substantial growth due to increasing healthcare infrastructure, awareness programs, and expansion of diagnostic services.

Related Report

Pediatric MRI Market Insights & Growth Forecast 2034